Vyriad, Inc.

Vyriad is a clinical-stage biotechnology company specializing in the development of targeted genetic therapies, including oncolytic virotherapy, in vivo gene therapy, and gene editing. The company leverages engineered virus platforms, such as vesicular stomatitis virus (VSV) and measles-based vectors, to selectively destroy cancer cells and trigger anti-tumor immune responses. Headquartered in Rochester, Minnesota, Vyriad maintains a cross-functional approach that integrates preclinical research, GMP manufacturing, and clinical development. The company collaborates with leading academic institutions and pharmaceutical partners to advance its pipeline, which includes both monotherapy and combination regimens for various cancer indications.